Anagenics Limited announced Matthew Dudek (CFO) will absorb the role of Company Secretary effective immediately and is continuing to pursue other profit improvement initiatives. In view of continuing focus on profit improvement and cost reduction Dr. Martin Cross has offered to resign as a director following the completion of the Company's 2023 Annual General Meeting. Dr. Cross joined the AN1 board in October 2017 and has contributed to the strategic direction of the business in a non-executive director capacity.

Martin has been an extremely valuable and supportive Director during his tenure and the Board acknowledges his many contributions over the past 6 years and his valuable industry networks and insights.